^
    Back
    Association details:
    Biomarker:PTBP1 overexpression
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    PTBP1 REGULATES ALTERNATIVE SPLICING OF APOPTOTIC PROTEIN: IMPLICATIONS IN CLL AND IBRUTINIB RESISTANCE

    Published date:
    05/14/2020
    Excerpt:
    PTBP1 was highly expressed in ibrutinib resistant MEC-1 cell line, as compared with parental cell (C).
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

    Published date:
    11/06/2019
    Excerpt:
    We further demonstrated that PTBP1 was aberrant expressed in ibrutinib resistant MEC-1 cell line or ibrutinib resistant primary patients' samples, as compared with parent cell line or patients' baseline samples.
    DOI:
    10.1182/blood-2019-126945